Articles by : Tom Mirga, Editor at Large

340B Drug Purchases Reached $53.7 Billion in 2022, HRSA Data Show

September 26, 2023 Tom Mirga, Editor at Large Views

Drug purchases under the 340B program totaled $53.7 billion in 2022, according to HRSA data obtained by Drug Channels.

Drug purchases under the 340B program totaled $53.7 billion in 2022, or 22.3% more than the $43.9 billion in 2021, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Health Center Challenging 340B Patient Definition Responds to HRSA’s and Drug Companies’ Court Arguments

September 19, 2023 Tom Mirga, Editor at Large Views

Genesis Health Care successfully challenged HRSA's 340B patient definition in the U.S. District Court for the District of South Carolina.

There is no evidence to support federal allegations that a South Carolina community health center illegally diverts 340B-purchased drugs to [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Novo Nordisk Providing 340B Refunds on Blockbuster Drug Ozempic

September 19, 2023 Tom Mirga, Editor at Large Views

Drugmaker Novo Nordisk is issuing 340B refunds for certain purchases of its blockbuster diabetes medication Ozempic.

Novo Nordisk will issue refunds to 340B covered entities for some purchases this year of its blockbuster injectable diabetes medication [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

HRSA Grants 340B Enrollment Flexibility in Georgia Due to Hurricane

September 14, 2023 Tom Mirga, Editor at Large Views

Hurricane Idalia cleanup in Uvalda, Georgia., on Aug. 31.

Eligible covered entities in Georgia may enroll in the 340B program immediately, rather than having to wait for the next [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Sanofi Withdraws Some Health Centers’ 340B Pricing at Contract Pharmacies

September 12, 2023 Tom Mirga, Editor at Large Views

Sanofi has recently denied some health centers access to 340B pricing at contract pharmacies after saying they did not conform to Sanofi's policy.

Drug manufacturer Sanofi recently started denying access for some health centers to 340B pricing at contract pharmacies after previously saying [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Merck Offering Refunds to 340B Covered Entities

September 12, 2023 Tom Mirga, Editor at Large Views

Merck is the first drug manufacturer to announce it is issuing refunds to 340B providers in 2024.

Drug manufacturer Merck recently announced that it owes refunds to 340B covered entities for purchases of 17 products during the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Sources Cited in Drugmakers’ Brief Question Accuracy in High-Profile 340B Patient Definition Case

September 8, 2023 Tom Mirga, Editor at Large Views

Genesis Health Care successfully challenged HRSA's 340B patient definition in the U.S. District Court for the District of South Carolina.

Inaccurate points were ascribed to 340B advisers and service providers in a recent legal filing by four drugmakers as part [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Janssen Issuing Refunds for 340B Overcharges

September 8, 2023 Tom Mirga, Editor at Large Views

Janssen Biotech is paying refunds for overcharges on certain 340B drugs purchased in the third quarter of 2020.

Drug manufacturer Janssen Biotech recently determined that it owes or may owe refunds to some 340B covered entities. The refunds [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Tolmar Providing Refunds for Five Years of 340B Overcharges

September 6, 2023 Tom Mirga, Editor at Large Views

Drugmaker Tolmar said it will refund 340B covered entities for overcharges on certain generic dermatologic products.

Drug manufacturer Tolmar recently said it plans refunds to 340B covered entities for overcharges on seven generic dermatologic products purchased [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

HRSA Again Selects Bizzell Group to Audit 340B Covered Entities

August 31, 2023 Tom Mirga, Editor at Large Views

Dr. Anton Bizzell is president and CEO of The Bizzell Group, which recently signed a contract with HRSA to continue auditing 340B covered entities.

The Health Resources and Services Administration (HRSA) has awarded a $25.3 million, five-year contract to The Bizzell Group to audit [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Site Footer Live